Jinxin Fertility Group (JXR) has announced that the new campus of its Shenzhen Zhongshan Maternity Hospital began trial operations on February 6, 2026. Located in the central area of Shenzhen, the new campus has a total floor area of 40,000 square meters, approximately four times the size of the original facility. The opening of the new campus provides a solid foundation for the sustained development of Shenzhen Zhongshan Maternity Hospital's business and significantly promotes its expansion into specialized service areas such as VIP services, specialized departments, and international medical services. Alongside the launch of the new campus, the Group's Shenzhen operations maintained strong growth momentum, with oocyte pickup (OPU) cycles in the first two months of 2026 increasing by 18% compared to the same period in 2025. In the United States, HRC Fertility clinics, managed by the Group under management service agreements, reported a year-on-year increase of approximately 38% in OPU cycles during the first two months of 2026. This growth is primarily attributed to increased local patient demand following the implementation of in vitro fertilization (IVF) insurance coverage under California Senate Bill 729 (SB729), which took effect in January 2026. The bill, originally scheduled to come into effect around July 2025, was subsequently delayed. Under SB729, large-group health insurance plans for employers with more than 100 employees are required to cover the diagnosis and treatment of infertility, while small and medium-sized employers may voluntarily opt in. Coverage includes three full OPU cycles and an unlimited number of embryo transfer cycles, with no distinctions based on marital status. The company will continue to advance operational optimization efforts, enhance clinical outcomes, focus on improving patient care and service quality, and accelerate the research, development, and upgrading of core reproductive technologies. Through these measures, the company is committed to creating long-term sustainable value for shareholders and contributing to the high-quality development of the industry.